Global Oligonucleotide Therapy Market Report 2022 – Featuring Biogen, GlaxoSmithKline and Pfizer Among Others – ResearchAndMarkets.com

Global Oligonucleotide Therapy Market Report 2022 – Featuring Biogen, GlaxoSmithKline and Pfizer Among Others – ResearchAndMarkets.com




Global Oligonucleotide Therapy Market Report 2022 – Featuring Biogen, GlaxoSmithKline and Pfizer Among Others – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Oligonucleotide Therapy Global Market Report 2022: By Type, By Application, By End-User” report has been added to ResearchAndMarkets.com’s offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global oligonucleotide therapy market.

This report focuses on oligonucleotide therapy market which is experiencing strong growth. The report gives a guide to the oligonucleotide therapy market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

The global oligonucleotide therapy market is expected to grow from $0.98 billion in 2021 to $1.10 billion in 2022 at a compound annual growth rate (CAGR) of 12.2%.

The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.86 billion in 2026 at a CAGR of 14.0%.

Companies Mentioned

  • Alnylam Pharmaceuticals Inc.
  • Biogen Inc.
  • Dynavax Technologies Corp.
  • Ionis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Miragen Therapeuutics Inc.
  • PCI Biotech Holdings ASA
  • Sarepta Therapeutics Inc.
  • Jazz Pharmaceuticals
  • Bausch & Lomb
  • Kastle Therapeutics
  • Akcea Therapeutics
  • Arrowhead Pharmaceuticals Inc.
  • GlaxoSmithKline plc.
  • SomaGenics inc.
  • Hepion Phrmaceuticals
  • Regulus Therapeutics Inc.
  • Gelead Sciences, Inc.
  • Santaris
  • InteRNA Technologies B.V.
  • Pfizer Inc.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

The oligonucleotide therapy market consists of sales of oligonucleotide therapy related services by entities (organizations, sole traders and partnerships) that manufacture oligonucleotide therapy products. Oligonucleotide therapy uses synthetic oligonucleotides, which can be artificially produced in labs, to inactivate disease-causing genes. Only goods and services traded between entities or sold to end consumers are included.

The main types of oligonucleotide therapy are antisense oligonucleotide, aptamer and other. Synthetic DNA oligomers called antisense oligonucleotides (AS ONs) hybridise to a target RNA in a sequence-specific method. They’ve been used to successfully limit gene expression, modify precursor messenger RNA splicing, and inactivate microRNAs. It is used in infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, others and is implemented in hospitals, research institutes.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oligonucleotide therapy market during the forecast period. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the oligonucleotide therapy market over the forthcoming years.

During the forecast period, the oligonucleotide therapy market was restrained by the low number of drug approvals by the FDA. As of January 2020, the market only had 11 drugs approved for treatment, thus restraining the growth of the market. This can be attributed to the strict standards for manufacturing and high drug efficacy standards set by the regulatory bodies for approval of this therapy, thus increasing the time required for approval and limiting the growth of the market.

The developers and providers of the oligonucleotide therapy market are investing in research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases. In August 2020, FDA granted accelerated approval to Viltepso (viltolarsen) injection, an antisense oligonucleotide for the treatment of Duchenne muscular dystrophy (DMD), which is a genetic disorder, with reduced side effects.

For more information about this report visit https://www.researchandmarkets.com/r/7vlo3d

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900